Literature DB >> 18501116

Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase.

Jing Shang1, Lu-lu Chen, Fang-xi Xiao, Hui Sun, Hong-cheng Ding, Hu Xiao.   

Abstract

AIM: To investigate whether resveratrol (RSV) can improve non-alcoholic fatty liver disease (NAFLD) and to find the possible mechanism.
METHODS: Rats fed a high-fat diet were treated with RSV. The liver histology was observed. Hyperinsulinemic euglycemic clamp was performed to assess insulin sensitivity. Fat accumulation was induced in HepG2 cells, and the cells were treated with RSV. AMP-activated protein kinase (AMPK) phosphorylation levels were determined both in the animal study and cell study.
RESULTS: Rats fed a high-fat diet developed abdominal obesity, NAFLD, and insulin resistance (IR), which were markedly improved by 10 weeks of RSV administration. RSV treatment prevented triacylglycerol (TG) accumulation in HepG2 cells that were incubated with high concentration of glucose and insulin. Both in vivo and in vitro studies showed that RSV treatment could promote the phosphorylation of AMPK, which in this study, suppressed 2 lipogenesis gene expressions, contributing to the improvement of NAFLD and IR.
CONCLUSION: The results indicated that by reducing TG accumulation and improving IR, RSV could protect the liver from NAFLD. The activation of AMPK was involved in the mechanism. RSV has the therapeutic potential for preventing or treating NAFLD and IR-related metabolic disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18501116     DOI: 10.1111/j.1745-7254.2008.00807.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  85 in total

Review 1.  Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease.

Authors:  Hui Dong; Fu-Er Lu; Li Zhao
Journal:  Chin J Integr Med       Date:  2012-02-05       Impact factor: 1.978

Review 2.  Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Authors:  Tannaz Eslamparast; Sareh Eghtesad; Hossein Poustchi; Azita Hekmatdoost
Journal:  World J Hepatol       Date:  2015-02-27

3.  Current status of therapy in nonalcoholic Fatty liver disease.

Authors:  Scott McNear; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

4.  The combination of resveratrol and quercetin enhances the individual effects of these molecules on triacylglycerol metabolism in white adipose tissue.

Authors:  Noemí Arias; M Teresa Macarulla; Leixuri Aguirre; Iñaki Milton; María P Portillo
Journal:  Eur J Nutr       Date:  2015-02-11       Impact factor: 5.614

5.  Targeting sirtuins for the treatment of diabetes.

Authors:  Frank K Huynh; Kathleen A Hershberger; Matthew D Hirschey
Journal:  Diabetes Manag (Lond)       Date:  2013-05-01

6.  Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway.

Authors:  Narasimman Gurusamy; Istvan Lekli; Subhendu Mukherjee; Diptarka Ray; Md Kaimul Ahsan; Mihaela Gherghiceanu; Lawrence M Popescu; Dipak K Das
Journal:  Cardiovasc Res       Date:  2009-12-03       Impact factor: 10.787

Review 7.  Role of cAMP and phosphodiesterase signaling in liver health and disease.

Authors:  Banrida Wahlang; Craig McClain; Shirish Barve; Leila Gobejishvili
Journal:  Cell Signal       Date:  2018-06-11       Impact factor: 4.315

8.  Alteration of FXR phosphorylation and sumoylation in liver in the development of adult catch-up growth.

Authors:  Xiang Hu; Qiao Zhang; Juan Zheng; Wen Kong; Hao-Hao Zhang; Tian-Shu Zeng; Jiao-Yue Zhang; Jie Min; Chaodong Wu; Lu-Lu Chen
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-24

9.  Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats.

Authors:  Ying Qin; Ya-ping Tian
Journal:  Lipids Health Dis       Date:  2010-07-26       Impact factor: 3.876

Review 10.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.